Increased expression of Cardiotrophin-1 in cardiomyopathy patients

Sharif, S; Saleem, A; Naz, S; Rashid, F; Iqtedar, M; Kaleem, A; Latif, A

doi:10.2478/bjmg-2021-0008

Abstract

Cardiomyopathy (CM) is a condition of cardiac dysfunction. It is one of the leading causes of mortality in which both genetic and environmental factors are involved. Cardiotrophin-1 (CT-1) level in plasma is associated with CM. It affects the cardiomyocyte differentiation. To evaluate the expression of CT-1 in cardiomyopathy, this study was done on CM subjects attending the Fatima Memorial Hospital, Lahore, Pakistan, between January and June, 2016. A total of 40 subjects were enrolled who were divided into two groups; CM group (n = 20) and a control group (n = 20). A self-designed questionnaire was filled in by each subject to collect data regarding age, body mass index (BMI) and CM history. RNA was isolated from blood after its quantification, cDNA was prepared and reverse-transcriptase-polymerase chain reaction (RT-PCR) was performed for expression of CT-1. The mean age in CM subjects was 40.1±6.03 years, while it was 35.0±3.7 years in the control group. The mean expression of CT-1 in the CM subjects was 5.2±0.66, while it was 1.00±0.001 in the control group. A highly significant difference was observed in CT-1 expression in the CM group, and expression was significantly correlated with age and BMI in CM subjects.

References

Colucci WS, Braunwald E. Heart failure: Cardiac function and dysfunction. In: Colucci WS, Editor. Atlas of Heart Diseases, 4th ed. Philadelphia, PA, USA: Blackwell Science. 1995: 128-142.
Search in Google Scholar Back to article
Maron BJ, Towbi, JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113(14): 1807-1816.
Search in Google Scholar Back to article
Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117(4): e25-e146.
Search in Google Scholar Back to article
Hershberger RE, Lindenfeld J, Mestroni, L, Seidman, CE, Taylor MR, Towbin JA; Heart Failure Society of America. Genetic evaluation of cardiomyopathy--A Heart Failure Society of America practice guideline. J Card Fail 2009; 15(2): 83-97.
Search in Google Scholar Back to article
Weigner M, Morgan JP. The causes of dilated cardiomyopathy. UpToDate. 2007; 15(3): 1-10.
Search in Google Scholar Back to article
Grenier MA, Osganian SK, Cox GF, Towbin JA, Colan SD, Lurie PR, et al. Design and implementation of the North American pediatric cardiomyopathy registry. Am Heart J. 2000; 139(2 Pt 3): s86-s95.
Search in Google Scholar Back to article
Watanabe T, Konii H, Sato K. Emerging roles of cardiotrophin-1 in the pathogenesis and biomarker of atherosclerosis. J. 2018; 1(1): 94-105.
Search in Google Scholar Back to article
Abdul-Ghani M, Suen C, Jiang B, Deng Y, Wedrick JJ, Putinski C, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017; 27(10): 1195-1215.
Search in Google Scholar Back to article
Konii H, Sato K, Kikuchi S, Okiyama H, Watanabe R, Hasegawa A, et al. Stimulatory effects of cardiotrophin 1 on atheroscheloris. Hypertension. 2013; 62(5): 942-950.
Search in Google Scholar Back to article
Chomczynski P, Mackey K. Short technical reports. Modificatin of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques. 1995; 19(6): 942-945.
Search in Google Scholar Back to article
Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: A cardiac myosin heavy chain gene missense mutation. Cell. 1999; 62(5): 999-1006.
Search in Google Scholar Back to article
Thomas DE, Wheeler R, Yousef ZR, Masami ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr. 2009; 10(8): 15-21.
Search in Google Scholar Back to article
Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, et al. Epidemiology of idiopathic cardiomyopathy in Japan: Results from a nationwide survey. Heart. 2002; 87(2): 126-130.
Search in Google Scholar Back to article
Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC Jr. Augmented cardiac cardio-trophin-1 in experimental congestive heart failure. Circulation. 2000; 101(1): 14-17.
Search in Google Scholar Back to article
Freed DH, Cunnington RH, Dangerfield AL, Sutton JS, Dixon IMC. Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc Res. 2005; 65(4): 782-792.
Search in Google Scholar Back to article
Natal C, Antonia Fortuño M, Restituto P, Bazán A, Colina I, Díez J, et al. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2008; 294(1): 52-60.
Search in Google Scholar Back to article
Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001; 38(5): 1485-90.
Search in Google Scholar Back to article

Increased expression of Cardiotrophin-1 in cardiomyopathy patients

Abstract

Paradigm

My account